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1124-95 Reticulated Platelets in Acute Coronary Syndrome: A 
Potential Marker for Platelet Consumption 
V&xi Tsyboulev, J. Jorgenssen, Abdus Saleem, Nasser M. Lakkia Baylor College Of 
Medicine, Houston, TX 
Introduction: The physiologic sequalae of damage to the vascular endothelium which 
include platelet adhesion to subendothelial elements in the blood vessel wall, recruitment 
of circulating platelets to form a hemostatic plug, and its subsequent consolidation with 
fibrin strands are now well established. We hypothesize that the presence of circulating 
reticulated (containing-RNA) platelets is potentially a reliable marker for platelet aggrega- 
tlon and thrombus formation in acute coronary syndrome. 
Methods Forty-seven subjects (15 controls, 32 patients with acute coronary syndrome) 
were studied. All patients had chest pain within 24 hours along with lschemic ST changes 
on the ECG or evidence of myocardial injury. Blood was collected for platelet count, 
mean platelet volume, and for flow cytometric analysis for the presence of reticulated 
platelets as assessed by uptake thiazole orange, and the expression of CD4la for the 
GPllbillla receptor on the platelet membrane. All studies were repeated in the presence 
of RNA-ase with evidence of 90% decrease of thiazole orange uptake, 
Results The mean platelet count was 220+32 in the control group and 207*45 in the 
acute coronary syndrome patients. The mean platelet volume was statistically higher in 
pabents than in controls (IO&l fl vs. 9&0.5 fl. p=O.OOS). Sixteen percent of the overall 
platelet population was reticulated in the acute coronary syndrome group compared to 
only 3 percent in the control group. Patients admitted with ST-elevation acute coronary 
syndrome had more reticulated platelets than those with non- ST-elevation (21.3i6.9 vs. 
14.9*6.9, p=O.Ol). Also, diabetic patients presenting with acute coronary syndrome had 
a significantly higher percentage of circulating reticulated platelets compared to non dia- 
betic patients (p=O.O003). Aspinn seems to eliminate these differences. 
Conclusion: Reticulated platelets appear to be a reliable marker for platelet aggregation 
and consumption in acute coronary syndrome. More studies are needed to further under- 
stand this novel observation. 
1124-114 EARLY Platelet Substudy 
Paul A. Gurbel, Raymond D. Bahr, Matt T. Roe, Victor L. Serbruany, Alex I. Maknin, W. 
8. Gibler, E. M. Ohman, Sinai Center for Thrombosis Research, Baltimore, MD, Duke 
University Medical Center, Durham, NC 
Background: Receptors other than GP Ilb/llla may mediate leukocyte-platelet-endothe- 
lial interactions that obstruct the microvasculature in acute coronary syndromes (ACS) 
and cause microinfarcts. The effect of eptifibatide (EP) on these receptors was investi- 
gated in the EARLY trial. Methods: Platelet receptors (mean fluorescense intensity) and 
aggregation (1% mol ADP) were determined at baseline, and at 3,6,12 and 24 hours 
after randomization to early (E) ( ID the Emergency Department, n=27) or late (L) (12-24 
hours, n=28) EP therapy. ResuI1s: Aggregation was inhibited by early EP (baseline, 72 * 
20% ; 3 hours post, 7i 9 %p<O.OOl). CD31, CD63, CD 107a, CD 107b. CD 41 (GPllbillla 
expression), and CD 62p were not affected in either group. Leukocyte-platelet aggre- 
gates trended upward after presentation (early baseline, 43.1* 26.0 versus 65.8 k35.6, 
p= 09). PAC.1 (GPllbillla activity), CD 51/61 (vitronectin receptor and CD 42b (GP lb) 
were inhibited by EP (pc.05). Conclusion: In Emergency Dept patients with ACS, EP 
rapidly and profoundly inhibits platelet aggregation and reduces GP Ilb/llla activity and 
the expression of CD51/61 and CD 42b; the latter two effects may also contribute to the 
drug’s anti-thrombotic effect. However, platelet-leukocyte aggregate formation, a marker 
of platelet activity rises within 24 hours after presentation despite eptifibatide therapy and 
is a potential mechanism for microvascular obstruction. 
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1124-115 Eptifibatide Provides Additional Platelet Inhibition in 
Non-ST Elevation Myocardial Infarction Patients 
Already Treated With Aspirin and Clopidogrel: Results 
of the PEACE Study 
Miles C. Dalby, Gilles Montalescot, Claire Bal-dit-Sollier. Eric Vicaut. Jean-Phillipe Collet, 
Remi Choussat, Vanessa Gallois, Gerard Drobinski, Ludovic Drouet, Daniel Thomas, 
Pitie Salpetriere Hospital, Paris, France 
Background: Thienopyridines and glycoprotein(Gp) Ilb/llla antagonists have been 
tested separately with success in the treatment of non ST elevation myocardlal infarction 
(NSTEMI). Although often co-prescribed in this context, the antiplatelet interaction of 
these agents is poorly described and the superiority of Gpllblllla antagomsts above 
thienopyridine treatment alone is not clear. The hypothesis of the study was that eptifi- 
batide offered further antlplatelet effect above clopidogrel in the medical stabilisation of 
NSTEMI prior to expeditive PCI. 
Methods: 32 NSTEMI patients treated with aspirin and enoxaparin were studied using 
flow-cytometry to define parameters of platelet activation with a panel of agonists before 
clopidogrel, following clopidogrel and during an eptifibatide infuslon. 
Results: With ADP, TRAP and U46. relative reductions in PAC-1 expression (conforma- 
tionally activated Gp Ilb/llla receptor) of 51%, 46% and 39% (all p<O.OOOl) respectively 
were seen with clopldogrel but a further 85%, 84% and 72% (all pcO.0001) reduction was 
seen with eptifibatide. Fibrinogen binding was significantly reduced followng clopidogrel 
by 77%, 63% and 69% (all p<O.OOOl) and again further reduced by 99% 98% and 98% 
(all pcO.0001) with eptifibatide. The total number of Gpllb/llla receptors (P2) and P-selec- 
tin expression were also reduced followng clopidogrel, with all agonists, (~~0.026, ADP 
and TRAP) however both parameters increased slightly in all cases with eptifibatide 
(p<O.O12 with ADP). 
Conclusion: The actwated Ilb/llla expression and fibrinogen binding findings indicate 
that eptifibatide provides significant potent antiplatelet activity above that of clopidogrel 
suggesting additive immediate protection in the treatment of NSTEMI. The P2 and P- 
selectin findings suggest the possibility of a partial agonist (and/or pro-inflammatory) 
effect, the consequences of which, with longer infusions are unknown. 
1124-l 16 Predictors of Early Mortality From an Unselected 
Patient Registry of Acute Coronary Syndromes 
(TRACS) 
James E. Calvin, Jr., Peter Meyers, Anthony Joseph, Allan Jaffe, TRACS Investigators, 
Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL 
Background: Several stratification models exist to predict early and late complications 
from an acute coronary syndrome (ACS). Most of these models are based on patient 
populations selected from randomued clinical trials and most are used to predict com- 
posite outcomes. The goal of this study was to determine predictors of mortality as a sol- 
itary end point in an unselected cohort of patients presenting to the Emergency 
Department (ED) with an ACS. 
Methods: The Registry of Acute Coronary Syndromes (TRACS) represents a dataset of 
all patients presenting with an ACS to the ED of 9 parlicipating centers. 
Results: Three thousand four hundred sixty four patients of whom 60% were male and 
17% were minorities comprised the TRACS registry. Sixty two percent were admitted. 
The in-hospital mortality rate for admitted patients was 9%. Patients who died in-hospital 
were older (72 YS 67 y. p = < .OOl), more likely Caucasian (90% vs 82%, p= .013), and 
more likely to have an elevated troponin I (64% vs 46%, p= < ,001). Conventional risk 
factors were similar but non-survivors received beta-blockers (36% vs 44% p = < ,021). 
nitrates (27% vs 54% p < .OOl), Ilb/llla platelet blockers (4% vs 13%, p= q ,001) and IV 
nitrates in the ED (24% vs 44%, p < ,001) less often. Multivariate analysis revealed 
increased age (odds ratlo, 95 Cl’s; 1.02, 1 .Ol- 1.03; p c .OOl), and an elevated troponin 
(1.866, 1.32. 2.60; p <. 001) to be associated with Increased mortality while in-hospital 
Ilb/llla use (.28. .12- .65; p= ,003) and IV nitrate use in the ED (.44, .33-.59: p< ,001) 
were associated wth reduced mortality. 
Conclusion: In this unselected population of admitted acute coronary syndrome 
patients, mortality was associated wth age and elevated troponin levels while In-hospital 
use of llbillla platelet blockers and IV nitrate therapy were associated with hospital surv- 
vorship. These results reaffirm the prognoshc value of age and troponins and the value of 
more aggressive medical management. 
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1125-96 Performance of the Thrombolysis in Myocardial 
Infarction Risk Index for Early Acute Coronary 
Syndrome in the National Registry of Myocardial 
Infarction: A Simple Risk Index Predicts Mortality in 
Both ST and Non-ST Elevation Myocardial Infarction 
Stephen D. Wiviott, David A. Morrow, Robert P. Giugliano, Paul D. Frederick, Carolyn H. 
McCabe, Christopher P. Cannon, Elliott M. Antman, Eugene Braunwald, Brigham & 
Women’s Hospital, Boston, MA 
Background: A simple risk Index (heart rate x [Age/lO]?SBP) developed from patients 
with ST elevation myocardial Infarction (STEMI) accurately predicts mortality in clirwal 
trials of fibrinolysls, but has not been evaluated in a general population with STEMI or 
non-ST elevation Ml (NSTEMI). 
Methods: To evaluate the TIMI Risk Index (TRI) I” such a population in the US, we 
tested it in the National Registry of Myocardial Infarction (NRMI) 3 and 4. NRMI patients 
were divided into pre-defined risk groups based on the derivation set from patietns 
receiving fibrinolysls in InTIME Il. 
Results: 117,676 patients with STEMI and 238,815 with NSTEMI were eligible for analy- 
sis. NRMI STEMI patients had a higher risk profile than those in the derivation set 
(Median TRI: 27 vs. 20). Dlwsion of those with STEMI into 5 pre-defined risk groups 
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revealed a strong graded mortality relationship (Range: 1 .O to 23.1%, p c.0001, c-statis- 1.43). This study confirms, in a large unselected cohort of HR-pts with AMI, that D is a 
tic 0.73). The predidive capacity of the TRI was particularly strong in lhose receiving rep- significant independent predictor of poor prognosis. Neverthless, pts with D are often 
erfusion therapy (STEMI-IRS, Fig A). Moreover, in patients with NSTEMI, the risk index undertreated with aggressive mechanical or pharmacological therapy. 
also revealed a significant graded relationship with mortality (Fig 6). 
Conclusions: A simple risk index from baseline clinical variables routinely obtained at 
the first patient encounter predicted mortality in a heterogeneous group of patients pre- a l-I=*- 
senting with STEMI or NSTEMI. Despite differences in syndrome pathophysiology, this _M”R, 
risk index may prove valuable in the assessment of patients with STEMI or NSTEMI. Ln 
1125-97 Thrombolysis in Myocardial Infarction Risk Score and 
ST Resolution Are Independent Predictors of Mortality 
1125-99 - Unraveling the Spectrum of Left Bundle Branch Block in 
Acute Myocaridal Infarction: Insights From ASSENT 3 
Francoise Boutot Jean Marie Caussanel, Emmanuel Pereira. Kolia Milojevic, Jean Marc 
Bayer. Yves Lambed, Versailles Hospital, Le Chesnay. France 
Background : Previous studies confirmed ST segment resolution (RST) during fibrinolyijc 
therapy (FT) for ST elevation myocardial infarction as a convenient marker of reperfusion 
correlated to TIMI flow grade and TIMI myocardial perfusion grade. The RST at 60, 90 
and 160 min after repedusion therapy is known to identify low mortality group of 
patients.The TIMI risk score is a clinical, bedside, risk score developped to predrct 
STEMI 30 days mortality. 
Objectives : The aim of this study is to assess the relationship between TIMI risk score 
and 60 min RST. 
Method : A cohort of 726 patients were given pre-hospital FT for STEMI (pain to FT, 
mean time 120 min). ECG was performed prior starting FT (baseline ECG) and 60 min 
later. ECG were analized to isolate two classes of RST: no or worsening RST (~30%) 
and partial or complete RST ()=30%). TIMI risk score was calculated at pre-hospital pre- 
sentation. 30 days mortality was investigated for each class of RST and each level of 
TIMI risk score. 
Results: The results are shown in the table below, and expressed in number of patients. 
TIMI risk score and 60 min RST are independent 30 days mortality markers(p>0.05). 
Conclusion : The absence of relationship between TIMI risk score and 60 min RST for 
STEMI patients suggests that RST should be taken into account as an independent vari- 
able in a new scoring system. 
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Hassam F. Al-Faleh, Yuling Fu, Galen S. Wagner, Shaun G. Goodman, E. Sgarbossa, 
Christopher B. Granger, Frans J. Van de Wed, Lars Wakentin, Paul W. Armstrong, For 
the ASSENT 3 Investigators, University of Alberta, Edmonton, AB. Canada 
Left bundle branch block (LBBB) complicates AMI diagnosis. Sgarbossa’s criteria devel- 
oped from GUSTO 1 to surmount this diagnostic challenge but have not been previously 
validated in a clinical trial. We evaluated their utility in the diagnosis and rusk stratifk?atlon 
of AMI patients (pts) in ASSENT 3. Methods: Baseline ECGs of ASSENT 3 pts were 
reviewed for LBBB by blinded core labs. Sequential ECGs (baselme, 60, 160 min & dis- 
charge) of LBBB pts were scored using Sgarbossa’s criteria (O-5) for AMI diagnosis. 
Results: 92(1.5%) pts had LBBB on baseline ECG: their 30-day death vs those without 
LBBB (n= 5932) was 14.1% vs 5.6% respectively (p=O.O03). More pts without peak CK 
>= 2x upper normal limit (UNL) had LBBB than those without LBBB (33.3% vs. 15.7%, 
p<O.OOl). Among 75 LBBB pts with peak CK data available, 30 day death tended to be 
lower among pts without peak CK rise than those with CK rise (4% versus la%, p=O.15). 
The table shows Sgarbossa’s score of >= 3 distribution (highly suggests AMI in the pres- 
ence of LBBB) and mortality. Sequenttal ECGs revealed that among 25 LBEB pts without 
peak CK rise, 15 pts did not have acute Ml on admission. 
Sgarbossa score ~3 Sgarbossa score <3 P value 
N=26 N=47 
Peak CK <2x 2 (7.2%) 23 (46.9%) <O.OOi 
Peak GK s=2x and 7 (14.9%) 
<=3x 
PeakCK>Bxandc=Sx 3 (10.7%) 7 (14.9%) 
Peak CK >5x 23 (62.1%) 10 (21.3%) 
30 day mortakty 6/28 (21.4%) 4147 (8.5%) 0.161 
Conclusion: Our findings validate the utrlity of Sgarbossa’s cntena for diagnosing AMI III 
the setting of LBBB. Sgarbossa’s criteria provide a sample and practical diagnostic 
approach to optimize risk- benefit of acute therapy in this diagnostically challenging 
group and contribute usefully to risk stratrfication in this high nsk population. 
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1125-98 One-Year Outcome of High-Risk Patients With Acute 
Myocardial Infarction With or Without Diabetes: Data 
1126 
From the MISTRAL Study 
Unstable Angina/Acute Myocardial 
Infarction: Prognosis 
Samuele Baldasseroni, Giuseppe Steffenino, Francesco Chiarella, Giovanni Maria 
Santoro, Antonio L. Bartorelli, Maria Luisa Laudisa, Donata Lucci. Aldo P. Maggioni, on 
behalf of MISTRAL Investigators, ANMCO Research Center, Florence, Italy 
Pts with diabetes (D) have more often severe coronary arteriosclerosis with high risk 
IHR) of AMI and cardiac death. We studied in-hosoital and I-Year outcomes of HR ots 
Aith’AMI with or without D treated with reperfusion therapy (thrombolysis or primary-P&) 
or drua theraw. 2227 HR-ots with AMI <I2 h were recruited at 17 centres wrth. and 30 
without, feasibility of performing primary PCI (classified at HR having21 of the following 
characteristics: female r70 y, diabetic >70 y, Killip class >I, SBP <IO0 mmHg and heart 
rate >lOO b/m, z-4 leads with ST deviation, previous Q-wave AMI, contraindication to 
thrombolysis). 1795 pts (60.6%) had not D and 432 pts (19.4%) were diabetic: pts with D 
were more often females, older, with a history of cardiovascular disease, arrhythmias 
during hospital stay and heart failure at entry. Pts with D were less treated with reperfu- 
sion therapy (74.3% vs 63.0%, p<O.OOOi) and with betablockers at discharge (41.2% vs 
49.5%, p<O.O05). One year mortality and combined end-point (death+reAMl+heart fail- 
ure+angina) are showed in the figure. When we adjusted the 1 -year outcomes for all clin- 
ical, haemodynamic variables and therapy, D remained an independent prognostic 
predictor (death OR: 1.54, 95%CI 1.13-2.09: combined end-point OR: 1.13, 95%CI 0.69- 
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1126-100 Increase in Mortality of Patients Discharged With the 
Diagnosis of Acute Myocardial Infarction Between 1986 
and 1996 
John 6. Kostis, Alan C. Wilson, Janet Lawrence-Nelson, Rajiv Ranjan, Nora M. 
Cosgrove, Clifton R. Lacy, Pearl D’Sa, UMDNJ-Robert Wood Johnson Medical School, 
New Brunswick, NJ 
Background: In-hospital mortality of acute myocardial infarction (Ml) has declined in the 
last 15 years. This study focuses on the outcome of patients after discharge. 
Methods: Using a statewide Ml database, we examined post-discharge mortality among 
30,341 Ml patients who were hospitalized in New Jersey from 1966 and 1996. 
Results: In 1996 patients were older and more likely to have non-Q MI. revascularization, 
comorbidity and shorter length of stay. Age adjusted one year mortality after discharge 
was higher in 1996 compared with 1966 (RR 1.06, 95% Cl 1.01-l .16). The increase per- 
sisted after adjustment for demographics, comorbidities, complications, procedures and 
age of infarction (RR 1.54, 95% Cl 1.42-1.67). The increased post-discharge mortality 
diminished the benefit of the marked decline of in-hospital mortality from 3.6% absolute 
